Overview
EIKN market data
Price History
EIKN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.01 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.99 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.90 – $17.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $526.8M.
Company News
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4Benzinga · Aug 14, 2026, 1:21 PM
8-K filing — Eikon Therapeutics, Inc. (EIKN)SEC EDGAR · Aug 14, 2026, 12:44 AM
Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) EstimateBenzinga · Aug 13, 2026, 8:21 PM
Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 TrialBenzinga · Aug 11, 2026, 11:32 AM
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In JuneBenzinga · Jul 27, 2026, 4:22 PM
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On MondayBenzinga · Jul 27, 2026, 2:35 PM
Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.Benzinga · Jul 27, 2026, 2:19 PM
Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung CancerBenzinga · Jul 27, 2026, 11:36 AM
Eikon Therapeutics Set To Join Russell 3000 Index, Effective JuneBenzinga · Jun 25, 2026, 8:20 PM